Mizuho raised the firm’s price target on Glaukos to $100 from $85 and keeps a Neutral rating on the shares ahead of the Q1 report. The analyst cites more bullish sentiment on early iDose trends post the recent reimbursement announcements for the target increase.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
